StreetAlpha.app
Home › Stocks › PROK

Prokidney Corp. (PROK)

Healthcare
$1.04
▼ −1.89%
LAST CLOSE · NOV 20

ProKidney develops rilparencel, a cell therapy aimed at preserving kidney function in people with chronic kidney disease and diabetes. It last closed at $1.04 on Nov 20, down 1.89% on the day. The next earnings report for PROK is expected around Wed, Mar 17, 2027, after the close. Over its last 8 reports the stock moved an average of 5.9% the session after earnings. Over the last 12 months PROK insiders bought $0 of stock on the open market and sold $1.1M, according to SEC Form 4 filings.

AI Auto Pilots
Is PROK in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold PROK.

Key Stats

Last 12 months
Results
Revenue
$775K
+4.2% vs a year ago
Net income
−$103.3M
−13326.7% margin
Free cash flow
−$167.8M
−21655.0% margin
Operating margin
−24830.3%
−$192.4M operating income
Balance sheet
Cash & equivalents
$81.4M
At Sep 30
Shareholder equity
−$906.9M
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $76K$76KFY2024FY2025: $893K$893KFY2025

From PROK's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Next report
Mar 17
Estimated date · After the close
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$174,000
−19.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $76,000Dec '24Mar 2025: $230,000Mar '25Jun 2025: $221,000Jun '25Sep 2025: $217,000Sep '25Dec 2025: $225,000Dec '25Mar 2026: $226,000Mar '26Jun 2026: $150,000Jun '26Sep 2026: $174,000Sep '26Latest $174,000
How PROK moved after its last 8 reports
Average move the session after a report ±5.9%
Nov 9, 2026Time not announced+0.9%
Aug 10, 2026After the close−4.7%
May 15, 2026Time not announced−2.9%
Mar 18, 2026After the close−6.3%
Nov 10, 2025After the close+3.7%
Aug 12, 2025After the close+5.8%
May 12, 2025After the close+15.8%
Mar 17, 2025After the close−6.8%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on PROKStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on PROK
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on PROK

Technical Analysis

PROK · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 39% below its 50 day average. It is 68% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the Pivot S1 at $1.02, and the nearest resistance the Pivot at $1.05.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityHigh, 11.1%/day
Key levels
$2.6552 week high+154.8%
$1.74200 day average+67.3%
$1.56100 day average+50.0%
$1.4550 day average+39.4%
$1.27Swing high (Nov 9)+22.1%
$1.1820 day average+13.5%
$1.07Pivot R1+2.9%
$1.05Pivot+1.0%
$1.04Last close
$1.02Pivot S1−1.9%
$1.01Swing low (Nov 16)−2.9%
$0.8752 week low−16.3%
Indicators
RSI (14)36.02Weak, oversold below 30Neutral
MACD-0.12Below its signal lineBearish
Stochastic27.7Middle of its rangeNeutral
ADX (14)27.6Trending down
Williams %R-85.2Oversold below −80, overbought above −20Oversold
CCI (20)-67.6Oversold below −100, overbought above 100Neutral
Rate of change−8.8%Change over 10 sessionsBearish
ATR (14)$0.11Typical daily range, 11.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PROK

What happened before

See how PROK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow PROK usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How PROK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for PROKHow many large options trades hit PROK, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

PROK Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲57 buying vs 27 selling
  • ▲Shares held by funds +13.7%
  • ▲Funds holding +20
  • ▼Superinvestors: 0 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding9272+27.8%
In funds' top 1001−100.0%
Held by funds–––
New / increased26 / 3122 / 26+18.8%
Reduced / sold out20 / 711 / 21−15.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PROK institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

PROK Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$1.1M1 sale · 1 insider
2026-08 sold $1.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Aug 20Brian JG PereiraDirectorSale757,164$1.41$1.1M
Nov 13, 2025Brian JG PereiraDirectorSale757,162$2.49$1.9M
Jul 8, 2025Darin J. WeberChief Regulatory OfficerSale plan103,480$3.02$313K
Apr 22, 2025Empresarial de Capitales S.A. de C.V. Control10% ownerBuy387,393$0.71$275K
Apr 17, 2025Empresarial de Capitales S.A. de C.V. Control10% ownerBuy25,000$0.75$19K
Apr 16, 2025Empresarial de Capitales S.A. de C.V. Control10% ownerBuy100,000$0.75$75K
Every insider buy and sale for PROK over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See PROK insider trades →

From SEC Form 4 filings by PROK's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PROK is in one of them and how their past PROK trades turned out.

PROK in the AI portfolios
Loading…

PROK News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PROK in an article yet. Here's the latest on the wider market.

PROK in the news

About Prokidney

ProKidney is a biotechnology company developing rilparencel, a cell therapy meant to preserve kidney function in patients with chronic kidney disease and type 2 diabetes. The treatment is made from a patient's own kidney cells, which are collected from a small kidney biopsy, processed at the company's facility, and then injected back into the kidneys. The company is based in Winston-Salem, North Carolina, and its product is still in clinical development.

Headquarters
Winston-Salem, NC